Interleukin-7
Trials 34 · a red edge is where a trial was stopped
Evidence & citations 19 cited values
Every value below carries the sentence it was read from. 42 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | interleukin-7 | “A Multicenter, Open-labeled, Controlled, Randomized Study of Recombinant Interleukin-7 (CYT107) Treatment to Restore and Maintain CD4 T-lymphocyte Counts Above 500 Cells/µL in...” NCT01241643 ↗23“Interleukin-7 (IL-7) has critical and nonredundant roles in T-cell development, hematopoiesis, and postdevelopmental immune functions as a prototypic homeostatic cytokine.” PMID 20068111 ↗ Jan 2010 “This is a Phase I/IIa inter-patient dose-escalation study assessing weekly doses of Interleukin-7 (CYT107) in HBeAg-negative chronic hepatitis B infected adult patients.” NCT01027065 ↗ “The purpose of this study is to determine the safety of a single, under-the-skin dose of interleukin-7 (IL-7) in HIV infected people currently taking anti-HIV drugs.” NCT00099671 ↗ “This study will evaluate whether interleukin-7 (IL-7) a drug similar to the natural IL-7 protein produced by the body, is safe to use in people infected with HIV.” NCT00105417 ↗ “Interleukin-7 (IL-7) is a common gamma chain receptor cytokine implicated in thymopoiesis and in peripheral expansion and survival of T lymphocytes.” PMID 19380868 ↗ Apr 2009 “Animal studies have shown that an experimental drug Interleukin 7 (IL-7), which is named CYT107, can increase the number and function of T cells.” NCT00839436 ↗ “Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma” NCT07308886 ↗ “Interleukin-7 (CYT 107) 20 microgram/kg / dose, by intramuscular (IM) injection” NCT01339000 ↗ “recombinant human Interleukin-7 (r-hIL-7 / CYT107) at a 20 µg/kg dose” NCT01019551 ↗ |
| Known as | CYT107 | “This is a Phase I inter-patient dose-escalation study assessing weekly doses of Interleukin-7 (CYT107) in adult patients infected by Genotype 1 Virus of Hepatitis C and...” NCT01025596 ↗18“This is a Phase I/IIa inter-patient dose-escalation study assessing weekly doses of Interleukin-7 (CYT107) in adult patients infected by virus genotype 1 or 4 of Hepatitis C...” NCT01025297 ↗ “A Multicenter Phase II Study of Enhancement of Immune Reconstitution and Vaccine Responses With Administration of Glyco-Recombinant Human IL-7(CYT107) in Older Subjects...” NCT01339000 ↗ “To determine the safety and establish the optimal biologic dose of glycosylated recombinant human interleukin-7 (CYT107).” NCT03941769 ↗ “Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma” NCT03513952 ↗ “This is a Phase I/IIa inter-patient dose-escalation study assessing weekly doses of Interleukin-7 (CYT107)” NCT01024894 ↗ “Recombinant Glycosylated Human Interleukin-7 (CYT107) After Completion of Standard Therapy” NCT01881867 ↗ “recombinant human Interleukin-7 (r-hIL-7 / CYT107) at a 20 µg/kg dose” NCT01019551 ↗ “CYT107 (r-hIL-7)” NCT00492440 ↗ |
| Known as | Glyco-r-hIL-7 | “A Phase Randomized Open Labelled Controlled Dose Escalation Study of Repeated Administration of "CYT107" (Glyco-r-hIL-7) Added on Antiviral Treatment and Vaccination in...” NCT01027065 ↗2“A PHASE I/IIa DOSE ESCALATION STUDY IN ASIA OF REPEATED ADMINISTRATION OF "CYT107" (Glyco-r-hIL-7) ADDED ON TREATMENT IN GENOTYPE 1 HCV INFECTED PATIENTS RESISTANT TO PEGYLATED...” NCT01025596 ↗ “A Phase I/IIa Dose Escalation Study of Repeated Administration of "CYT107" (Glyco-r-hIL-7) Add-On Treatment in Genotype 1 or 4 Hcv Infected Patients Resistant to Pegylated...” NCT01025297 ↗ |
| Known as | Glyco-Recombinant Human IL-7 | “A Multicenter Phase II Study of Enhancement of Immune Reconstitution and Vaccine Responses With Administration of Glyco-Recombinant Human IL-7(CYT107) in Older Subjects...” NCT01339000 ↗ |
| Known as | Glycosylated Recombinant Human Interleukin-7 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01881867 ↗ |
| Known as | IL-7 | “A Multicenter Phase II Study of Enhancement of Immune Reconstitution and Vaccine Responses With Administration of Glyco-Recombinant Human IL-7(CYT107) in Older Subjects...” NCT01339000 ↗10“METHODS: We conducted a prospective, double-blind, randomized, placebo-controlled trial of CYT107, recombinant human IL-7, in 109 critically ill, patients with lymphopenia who...” PMID 39903535 ↗ Feb 2025 “Determine the maximum tolerated dose of interleukin-7 (IL-7) when administered with melanoma peptide vaccine emulsified in Montanide ISA-51 in patients with metastatic melanoma.” NCT00091338 ↗ “Interleukin-7 (IL-7) has critical and nonredundant roles in T-cell development, hematopoiesis, and postdevelopmental immune functions as a prototypic homeostatic cytokine.” PMID 20068111 ↗ Jan 2010 “The purpose of this study is to determine the safety of a single, under-the-skin dose of interleukin-7 (IL-7) in HIV infected people currently taking anti-HIV drugs.” NCT00099671 ↗ “Interleukin-7 (IL-7) is a common gamma chain receptor cytokine implicated in thymopoiesis and in peripheral expansion and survival of T lymphocytes.” PMID 19380868 ↗ Apr 2009 “Animal studies have shown that an experimental drug Interleukin 7 (IL-7), which is named CYT107, can increase the number and function of T cells.” NCT00839436 ↗ “This study will evaluate the safety of a new experimental drug, IL-7, in people with HCV infection resistant after 12 weeks of bi-therapy.” NCT01025596 ↗ “parenteral administration of recombinant Interleukin-7 (IL-7) (CYT107)” NCT04154826 ↗ “Interleukin-7 (IL-7) is an antiapoptotic common γ-chain cytokine” PMID 29515037 ↗ Mar 2018 |
| Known as | Interleukin 7 glycosylated | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297772 ↗ |
| Known as | Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03929107 ↗ |
| Known as | Interleukin-7 human recombinant | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297772 ↗ |
| Known as | Recombinant Glycosylated Human Interleukin-7 | “Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma” NCT07308886 ↗ |
| Known as | Recombinant hIL-7 | “Recombinant hIL-7 induced CD4 and CD8 T cells to enter cell cycle;” PMID 19380868 ↗ Apr 2009 |
| Known as | recombinant human IL-7 | “Patients received a total of 8 subcutaneous injections of 2 different doses of recombinant human IL-7 (rhIL-7; 3 or 10 microg/kg) 3 times per week over a 16-day period.” PMID 19287090 ↗ Mar 20093“A Randomized Phase II Study of Atezolizumab (MPDL3280A) Plus Recombinant Human IL7 (CYT107) in Patients With Locally Advanced or Metastatic Urothelial Carcinoma” NCT03513952 ↗ “We report here on the toxicity and biological activity of recombinant human IL-7 (rhIL-7) in humans.” PMID 20068111 ↗ Jan 2010 “recombinant human IL-7 (interleukin 7) (rhIL-7 (recombinant human interleukin 7))” NCT00923351 ↗ |
| Known as | recombinant human interleukin 7 | “single cycle of 3 weekly subcutaneous (s/c) injections of recombinant human interleukin 7 (r-hIL-7) is safe and improves immune CD4 T-cell restoration.” PMID 26908786 ↗ Feb 20162“Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation.” PMID 23012326 ↗ Sep 2012 “recombinant human IL-7 (interleukin 7) (rhIL-7 (recombinant human interleukin 7))” NCT00923351 ↗ |
| Known as | Recombinant Interleukin-7 | “A Multicenter, Open-labeled, Controlled, Randomized Study of Recombinant Interleukin-7 (CYT107) Treatment to Restore and Maintain CD4 T-lymphocyte Counts Above 500 Cells/µL in...” NCT01241643 ↗ |
| Known as | rhIL-7 | “Recombinant human interleukin-7 (rhIL-7) may play a role in immune reconstitution and immune enhancement in various circumstances of immune insufficiency in older individuals...” NCT01339000 ↗8“Patients received a total of 8 subcutaneous injections of 2 different doses of recombinant human IL-7 (rhIL-7; 3 or 10 microg/kg) 3 times per week over a 16-day period.” PMID 19287090 ↗ Mar 2009 “single cycle of 3 weekly subcutaneous (s/c) injections of recombinant human interleukin 7 (r-hIL-7) is safe and improves immune CD4 T-cell restoration.” PMID 26908786 ↗ Feb 2016 “The safety and activity of recombinant human IL-7 (rhIL-7) administration were therefore examined in HIV-infected persons.” PMID 19380868 ↗ Apr 2009 “We report here on the toxicity and biological activity of recombinant human IL-7 (rhIL-7) in humans.” PMID 20068111 ↗ Jan 2010 “We performed a phase 1 trial of r-hIL-7 (CYT107) in recipients of T-cell depleted allo-HSCTs.” PMID 23012326 ↗ Sep 2012 “recombinant human Interleukin-7 (r-hIL-7 / CYT107) at a 20 µg/kg dose” NCT01019551 ↗ “CYT107 (r-hIL-7)” NCT00492440 ↗ |
| Known as | Sh-polypeptide-42 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297772 ↗ |
| Action | Restore | “a single cycle of 3 weekly subcutaneous (s/c) injections of recombinant human interleukin 7 (r-hIL-7) is safe and improves immune CD4 T-cell restoration” PMID 26908786 ↗ Feb 2016 |
| Modality | Protein / enzyme biologic | “We report here on the toxicity and biological activity of recombinant human IL-7 (rhIL-7) in humans.” PMID 20068111 ↗ Jan 2010 |
| Route | Subcutaneous | “Patients receive interleukin-7 (IL-7) subcutaneously on days 0, 2, 4, 6, 8, 10, 12, and 14 (for a total of 8 doses)” NCT00062049 ↗ |